Stephen L. Sabba - 16 Jun 2026 Form 4 Insider Report for LIGAND PHARMACEUTICALS INC (LGND)

Reporting relationship: Director
Issuer ticker: LGND
Reported as of: 16 Jun 2026
Net transaction value: -$544,830
SEC form: 4
Accepted by SEC: 18 Jun 2026, 08:37:48 UTC
Prior SEC filing: 09 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Stephen L. Sabba

Key filing fact

Stephen L. Sabba filed Form 4 for LIGAND PHARMACEUTICALS INC (LGND) on 18 Jun 2026.

Key facts

This page summarizes Stephen L. Sabba's Form 4 filing for LIGAND PHARMACEUTICALS INC (LGND).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 18 Jun 2026, 08:37.

Change

Previous filing in this sequence was filed on 09 Jun 2026.
Current net transaction value: -$544,830.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001442372 Primary reporting owner

Sabba Stephen L

Relationship: Director
Address: 485 UNDERHILL BLVD SUITE 205, SYOSSET
Signature: /s/ Stephen L. Sabba
Signature date: 18 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

LGND transaction

Common Stock

Options Exercise

Transaction value
Shares: +2,145
Change %: +6.4%
Price: $66.13^*
Shares after: 35,774
Date: 16 Jun 2026
Ownership: Direct
Footnotes: F1

LGND transaction

Common Stock

Sale

Transaction value: $544,830
Shares: -2,145
Change %: -6%
Price: $254.00
Shares after: 33,629
Date: 16 Jun 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

LGND transaction Derivative

Non-Qualified Stock Option (right to buy)

Options Exercise

Transaction value
Shares: -2,145
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 16 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 2,145
Exercise price: $66.13
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

These securities, as represented in Column 5, include the grant of 836 restricted shares approved by the Board of Directors of the Company at the 2026 Meeting held 5 June 2026, which shares were previously reported on a Form 4 for this Reporting Person dated 9 June 2026.

Footnote F2

These securities, as represented in Column 5, were acquired by a grant of 2,456 shares approved by the Board of Directors of the Company at the 2017 Meeting, as previously reported on the Reporting Person's Form 4, dated 30 May 2017. That grant vested in full on the first anniversary of the grant date or immediately (x) upon a change in control or a hostile takeover of the Company or (y) the death or permanent disability of the grantee if still serving at that time. The original grant was adjusted to 2,145 shares and the exercise price adjusted to $66.13 pursuant to the OmniAb Inc. separation from the Company.